Published clinical studies suggest that germline BRCA mutation-associated (gBRCAm) breast cancers are more sensitive to DNA-damaging therapies like poly (adenosine diphosphate ribose) polymerase (PARP) inhibitors [9]. The gene discussed is PARP1; the disease is breast cancer.